These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8108223)
1. Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children. Block SL; Hedrick JA; Tyler RD; Smith RA; Calandra G; Patterson C; Lewis J; Sitrin R; Miller W; Schwartz S Pediatr Infect Dis J; 1993 Dec; 12(12):976-80. PubMed ID: 8108223 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children. Newcomer W; Rivin B; Reid R; Moulton LH; Wolff M; Croll J; Johnson C; Brown L; Nalin D; Santosham M Pediatr Infect Dis J; 1994 Jul; 13(7):640-2. PubMed ID: 7970954 [TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Castillo de Febres O; Chacon de Petrola M; Casanova de Escalona L; Naveda O; Naveda M; Estopinan M; Bordones G; Zambrano B; Garcia A; Dumas R Vaccine; 1999 Nov; 18(7-8):656-64. PubMed ID: 10547425 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Dagan R; Greenberg D; Goldenbertg-Gehtman P; Vidor E; Briantais P; Pinsk V; Athias O; Dumas R Vaccine; 1999 Apr; 17(15-16):1919-25. PubMed ID: 10217590 [TBL] [Abstract][Full Text] [Related]
5. Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. Ashur Y; Adler R; Rowe M; Shouval D Vaccine; 1999 May; 17(18):2290-6. PubMed ID: 10403597 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061 [TBL] [Abstract][Full Text] [Related]
7. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Shouval D; Ashur Y; Adler R; Lewis JA; Armstrong ME; Davide JP; McGuire B; Kuter B; Brown L; Miller W Vaccine; 1993; 11 Suppl 1():S9-14. PubMed ID: 8383390 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. Goilav C; Zuckerman J; Lafrenz M; Vidor E; Lauwers S; Ratheau C; Benichou G; Zuckerman A J Med Virol; 1995 Jul; 46(3):287-92. PubMed ID: 7561805 [TBL] [Abstract][Full Text] [Related]
9. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine. Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W Isr J Med Sci; 1994; 30(5-6):485-8. PubMed ID: 8034508 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. López EL; Del Carmen Xifró M; Torrado LE; De Rosa MF; Gómez R; Dumas R; Wood SC; Contrini MM Pediatr Infect Dis J; 2001 Jan; 20(1):48-52. PubMed ID: 11176566 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis A vaccine in healthy adults: a comparison of immunogenicity and reactogenicity between two- and three-dose regimens. Lu MY; Chang MH; Tsai KS; Chen DS Vaccine; 1999 Jan; 17(1):26-30. PubMed ID: 10078604 [TBL] [Abstract][Full Text] [Related]
12. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine. Theilmann L; Kallinowski B; Gmelin K; Hofmann F; Scheiermann N; Wohland B; Stickl H; Maiwald H; Moriabadi FK; Bock HL Vaccine; 1992; 10 Suppl 1():S132-4. PubMed ID: 1335644 [TBL] [Abstract][Full Text] [Related]
13. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Bryan JP; Henry CH; Hoffman AG; South-Paul JE; Smith JA; Cruess D; Spieker JM; de Medina M Vaccine; 2000 Nov; 19(7-8):743-50. PubMed ID: 11115695 [TBL] [Abstract][Full Text] [Related]
14. Comparative immunogenicity and tolerance of Vaqta and Havrix. Braconier JH; Wennerholm S; Norrby SR Vaccine; 1999 Apr; 17(17):2181-4. PubMed ID: 10367952 [TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. Shouval D; Ashur Y; Adler R; Lewis JA; Miller W; Kuter B; Brown L; Nalin DR J Hepatol; 1993; 18 Suppl 2():S32-7. PubMed ID: 8182270 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. Lee SD; Chan CY; Yu MI; Wang YJ; Chang FY; Lo KJ; Safary A J Med Virol; 1997 Jun; 52(2):215-8. PubMed ID: 9179771 [TBL] [Abstract][Full Text] [Related]
17. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Kanra G; Yalçin SS; Ceyhan M; Yurdakök K Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974 [TBL] [Abstract][Full Text] [Related]
18. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. Nalin DR; Kuter BJ; Brown L; Patterson C; Calandra GB; Werzberger A; Shouval D; Ellerbeck E; Block SL; Bishop R J Hepatol; 1993; 18 Suppl 2():S51-5. PubMed ID: 8182275 [TBL] [Abstract][Full Text] [Related]
19. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Goubau P; Van Gerven V; Safary A; Delem A; Knops J; D'Hondt E; André FE; Desmyter J Vaccine; 1992; 10 Suppl 1():S114-8. PubMed ID: 1335638 [TBL] [Abstract][Full Text] [Related]
20. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. Davidson M; Krugman S; Sandman LA Vaccine; 1992; 10 Suppl 1():S119-20. PubMed ID: 1335639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]